Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
Bone
|
June 1, 2024
Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal
Ilaria Tanasi, Lara Crosera, Francesco Taus, et al.
European Journal of Internal Medicine
|
October 18, 2021
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group
Fabio Cacciapaglia, Francesca Romana Spinelli, Matteo Piga, et al.
Clinical and Experimental Rheumatology
|
January 21, 2026
Parvovirus B19 infection with rheumatologic manifestations: results from a multicentre Italian study
Federico Aldegheri, Riccardo Bixio, Alessandro Volpe, et al.
Rheumatology (Oxford, England)
|
December 12, 2025
Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS (Voclosporin in Real Life Setting Study) experience
Luca Iaccarino, Aurora Di Gregorio, Marta Calatroni, et al.
Biologics : Targets & Therapy
|
November 5, 2025
Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0)
Marisol Bracalenti, Margherita Zen, Benedetta Bianchi, et al.
The Lancet. Rheumatology
|
November 1, 2024
Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework
Emanuel Della-Torre, Rosaria Talarico, Jose Ballarin, et al.
Lupus Science & Medicine
|
May 4, 2026
Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort
Greta Hulej, Federico Arru, Benedetta Bianchi, et al.
Journal of Autoimmunity
|
October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort
Mariele Gatto, Francesca Saccon, Laura Andreoli, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting
Mariele Gatto, Francesca Saccon, Margherita Zen, et al.
Journal of Personalized Medicine
|
April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)
Margherita Zen, Mariele Gatto, Roberto Depascale, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
Bone
|
June 1, 2024
Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal
Ilaria Tanasi, Lara Crosera, Francesco Taus, et al.
European Journal of Internal Medicine
|
October 18, 2021
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group
Fabio Cacciapaglia, Francesca Romana Spinelli, Matteo Piga, et al.
Clinical and Experimental Rheumatology
|
January 21, 2026
Parvovirus B19 infection with rheumatologic manifestations: results from a multicentre Italian study
Federico Aldegheri, Riccardo Bixio, Alessandro Volpe, et al.
Rheumatology (Oxford, England)
|
December 12, 2025
Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS (Voclosporin in Real Life Setting Study) experience
Luca Iaccarino, Aurora Di Gregorio, Marta Calatroni, et al.
Biologics : Targets & Therapy
|
November 5, 2025
Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0)
Marisol Bracalenti, Margherita Zen, Benedetta Bianchi, et al.
The Lancet. Rheumatology
|
November 1, 2024
Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework
Emanuel Della-Torre, Rosaria Talarico, Jose Ballarin, et al.
Lupus Science & Medicine
|
May 4, 2026
Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort
Greta Hulej, Federico Arru, Benedetta Bianchi, et al.
Journal of Autoimmunity
|
October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort
Mariele Gatto, Francesca Saccon, Laura Andreoli, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting
Mariele Gatto, Francesca Saccon, Margherita Zen, et al.
Journal of Personalized Medicine
|
April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)
Margherita Zen, Mariele Gatto, Roberto Depascale, et al.
Page
of 8